Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.

Abstract

B/myeloid mixed-phenotype acute leukemia (MPAL) is an uncommon and aggressive leukemia without well-established treatment guidelines and has an inferior outcome. Relapsed/refractory (R/R) acute myeloid leukemia (AML) that is ineligible for aggressive chemotherapy regimens and allogeneic hematopoietic stem-cell transplantation has an extremely poor prognosis. The novel regimen of venetoclax (VEN) combined with hypomethylating agents (HMAs) has a synergistic therapeutic effect and a tolerable safety profile, which has been officially approved by the US Food and Drug Administration (FDA) for newly diagnosed AML in adults who are 75 years or older or patients precluding intensive induction chemotherapy. For R/R and other rare types of AML, no consensus has been reached on the efficacy of VEN-HMA. In addition, there is no available report on treatment-naive B/myeloid MPAL with VEN-HMA. Herein, we present 3 cases of VEN-HMA in treatment-naive B/myeloid MPAL and R/R AML. Its potential efficacy is worthy of further exploration in future researches.

• Authors: Na Wang, Jing He, Fang Liu
• Journal: Chemotherapy (Chemotherapy) Vol. 67 Issue 3 Pg. 178-182 ( 2022) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 35306492 (Publication Type: Case Reports)
• Copyright: © 2022 The Author(s). Published by S. Karger AG, Basel.

Chemical References

• Bridged Bicyclo Compounds, Heterocyclic
• Sulfonamides
• venetoclax

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)
• Humans
• Leukemia, Myeloid, Acute (drug therapy, genetics)
• Phenotype
• Sulfonamides